Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Are currently enrolled and active in the originator study, 18001. A participant is considered active in the study if they are:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
279 participants in 1 patient group
There are currently no registered sites for this trial.
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Start date
May 01, 2025 • 1 day ago
Today
May 02, 2025
End date
May 01, 2030 • in 4 years
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal